SAN FRANCISCO, Dec. 1, 2010 /PRNewswire/ -- DecisionView Inc., a leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the release of DecisionView StudyOptimizer 4.2, the latest version of the company's flagship solution for patient enrollment planning, tracking and forecasting. By providing better insight into historical enrollment performance and future cost projections, StudyOptimizer 4.2 significantly improves the ability of global pharmaceutical customers to optimize enrollment plans and deliver clinical trials on time and on budget. And with new support for integration with industry-standard portals, customers can now get real-time, on-demand access to these insights across the enterprise.
"Both drug sponsors and clinical trial organizations are looking at the patient enrollment process as a clear opportunity to positively impact their bottom lines," said Alan Louie, Research Director at IDC Health Insights. "The challenge is that today, the majority of global clinical trials are planned and budgeted on spreadsheets and delivered chronically late and over budget. By implementing a discipline of accurate enrollment planning and forecasting across their global portfolio of studies, organizations can reduce enrollment variances and costs, as well as the need to 'rescue' problem trials, allowing them to deliver trials more consistently on time and on budget."
StudyOptimizer 4.2 delivers compelling new capabilities to optimize enrollment plans by providing better visibility into historical performance and future cost projections. In addition, new portal integration capabilities allow this information to be distributed to a wider audience within the enterprise. Specific new features include:
Investigator Historical Performance
This feature helps study planners understand how individual investigators have performed in trials conducted by an organization in the past, by analyzing screening and randomization performance data for all investigators within a given set of studies. This insight allows clinical trial managers to do a better job determining enrollment feasibility for a given trial, and helps organizations funnel studies towards high performing sites and investigators.
Enrollment Historical Performance
This feature makes historical enrollment performance metrics available "in context", while planners are entering assumptions for an upcoming clinical trial. This helps planners validate their enrollment modeling assumptions immediately, and thereby create more accurate and feasible plans.
Enrollment & Treatment Cost Analysis
This feature automatically calculates planned, accrued and projected costs for enrollment and treatment, based on expected cost assumptions. This allows enrollment planners to capture and forecast planned enrollment costs, visualize cost outlays, and track enrollment and treatment costs as a trial progresses.
Open Portal Integration
This feature enables StudyOptimizer visualizations and analytics information to be integrated into an enterprise portal to facilitate wider consumption of enrollment performance information across the enterprise. StudyOptimizer supports integration with a number of leading portals on the market through its support for JSR 286 and WSRP 2.0 standards
"The release of StudyOptimizer 4.2 further solidifies our leadership as a 'best-in-class' enrollment optimization solution," said Linda Drumright, President and Chief Operating Officer at DecisionView. "These new capabilities allow our customers to share the most accurate, up-to-date patient enrollment forecasts across the clinical operations organization and the entire enterprise. With this release, study teams will be able to share trial cost forecasts with the budgeting organization, historical trial and investigator metrics with feasibility and site selection functions, and enrollment tracking reports with senior management, strategic partners and outsourced providers."
DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView's flagship solution, StudyOptimizer, helps organizations optimize clinical trial enrollment by aggregating patient recruitment data from multiple sources and providing analytics, visualizations, and predictive scenario modeling that delivers unique and actionable insight. StudyOptimizer is used by 5 of the top 10 global pharmaceutical companies, and has been used on over 1,100 clinical studies with over 230,000 subjects enrolled in 13 different therapeutic areas. Investors in the company include Granite Ventures and Aeris Capital. For additional information about DecisionView, go to www.decisionview.com or call 415-538-1800.
SOURCE DecisionView Inc.